Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Animal studies have demonstrated that GLP-1 receptor agonists can increase sympathetic nerve activity, particularly to the heart and kidneys
The two systems support each other
Semaglutide is the top driver for prescription demand both in hospitals and retail pharmacies
Target Population Obese adults without diabetes No prior diagnosis of obesity-associated cancers Mean age: 47.2 years (SD 14.8) Study period: December 2014 to June 2025 Study Design Design: Target trial emulation using retrospective cohort data Database: TriNetX nationwide database of 113 million US patients Total cohort: 229,467 patients Matched cohort: 161,798 patients after 1:1 propensity score matching 80,899 GLP-1RA users 80,899 diet/exercise counseling controls Validation: Inverse probability of treatment weighting analysis Endpoints Primary endpoint: Cumulative incidence of 13 obesity-associated cancers between treatment groups Secondary endpoints: Cancer incidence stratified by: Sex (female vs
![glp-1 gip muscle preservation therapies 2025 Tirzepatide vs. Semaglutide: Which Better Preserves Muscle? [SURMOUNT-5 Data] Triple Agonism Based Therapies for –](https://www.geneticlifehacks.com/wp-content/uploads/2025/10/GLP-1_-Appetite-Insulin-and-Genetics.png)
